entertainment -WSS

entertainment

author：hotspot 2025-09-27 19:38:06 - browse：57859

Purple AML cells in blood flow — coverage from STAT — Acute myeloid leukemia cells amid blood flow. Adobe

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.

While the label means that physicians will have to have a conversation about secondary malignancies occurring after Carvykti treatment, oncologists and CAR-T experts said the label update won’t change anything about the use of Carvykti.

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti. That’s partly because physicians already discuss the risk of second cancers due to other cancer therapies including radiation, some targeted therapies, and some chemotherapies, which are necessary in the use of CAR-T. “We do have secondary primary malignancy discussions with patients in the context of transplant and will have to do for CAR-T as well,” Usmani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Sudafed saga points to U.S. issues with evaluating older drugs

focus

WSS

BridgeBio heart drug succeeds in pivotal study

Medicare drug price negotiation program allowed for now

Manchin plays down potential 3rd

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Medicare drug price negotiation program allowed for now

Covid vaccines: Private market messier than government rollout

hotspot

entertainment

Wikipedia

Psychedelics group wrestles with new pharma identity

Medicare drug price negotiation program allowed for now

Bright Health sells Medicare Advantage business to Molina

FDA seeks to regulate lab

Medicare details structure of new drug price negotiation program

How one patient went off dialysis — and others can too

The high cost of giving birth even with insurance

Flagship, Pfizer team up in deal worth up to $7 billion

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Covid vaccines: Private market messier than government rollout

explore

Twill hunts for pharma partner to market its depression app

Intercept Pharmaceuticals sells itself for less than $1 billion

ER docs worry over extreme heat as a 'mass casualty event'

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Why do women spend more than men on medical expenses?

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

focus

focus

focus

knowledge